BACKGROUND: Postpartum hemorrhage (PPH) is a potentially fatal complication of vaginal and cesarean deliveries. The active management of the third stage of labor provides administration of prophylactic uterotonic drugs just before or immediately after delivery, since they reduce the risk of PPH by 60%. OBJECTIVE: Overview on all available uterotonics for PPH prevention to clarify indications and contraindications in choice among drugs. SEARCH STRATEGY: Systematic review of the literature. MAIN RESULTS: Oxytocin is the first choice for PPH prophylaxis. Ergot alkaloids, syntometrine, and prostaglandins are second-line uterotonic agents. Misoprostol is not effective as oxytocin but it may be used when the latter is not available. Carbetocin should be used instead of continuous oxytocin infusion in elective cesarean sections for PPH prevention and to decrease the need for therapeutic uterotonics. CONCLUSIONS: Prophylactic oxytocics should be offered routinely in the third stage of labor in all women. The prophylactic use of uterotonics should be individualized.
BACKGROUND: Postpartum hemorrhage (PPH) is a potentially fatal complication of vaginal and cesarean deliveries. The active management of the third stage of labor provides administration of prophylactic uterotonic drugs just before or immediately after delivery, since they reduce the risk of PPH by 60%. OBJECTIVE: Overview on all available uterotonics for PPH prevention to clarify indications and contraindications in choice among drugs. SEARCH STRATEGY: Systematic review of the literature. MAIN RESULTS: Oxytocin is the first choice for PPH prophylaxis. Ergot alkaloids, syntometrine, and prostaglandins are second-line uterotonic agents. Misoprostol is not effective as oxytocin but it may be used when the latter is not available. Carbetocin should be used instead of continuous oxytocin infusion in elective cesarean sections for PPH prevention and to decrease the need for therapeutic uterotonics. CONCLUSIONS: Prophylactic oxytocics should be offered routinely in the third stage of labor in all women. The prophylactic use of uterotonics should be individualized.
Entities:
Keywords:
active management; blood loss prevention; postpartum hemorrhage; third stage of labor; uterotonic drugs
Authors: Marco Mrusek; Ean-Jeong Seo; Henry Johannes Greten; Michael Simon; Thomas Efferth Journal: Invest New Drugs Date: 2014-10-25 Impact factor: 3.850
Authors: Shajila Siricilla; Kelsi M Knapp; Jackson H Rogers; Courtney Berger; Elaine L Shelton; Dehui Mi; Paige Vinson; Jennifer Condon; Bibhash C Paria; Jeff Reese; Quanhu Sheng; Jennifer L Herington Journal: Pharmacol Res Date: 2019-05-09 Impact factor: 7.658
Authors: Salvatore Gizzo; Stefania Di Gangi; Marco Noventa; Veronica Bacile; Alessandra Zambon; Giovanni Battista Nardelli Journal: Biomed Res Int Date: 2014-05-15 Impact factor: 3.411
Authors: Bassel H Al Wattar; Jennifer A Tamblyn; William Parry-Smith; Mathew Prior; Helen Van Der Nelson Journal: Risk Manag Healthc Policy Date: 2017-01-17